Posted by Michael Wonder on 20 Mar 2018
NICE rejects rare eye disease drug
20 March 2018 - Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.
In patients with neurotrophic keratitis, damage to the nerve connected to the cornea causes sight loss and impairs healing.
Current treatments, such as artificial tears, help ease symptoms but as yet there is no cure available for the disease.
